Ginni Filaments: SBICAP Trustee Releases Encumbrance on 26.48 Lakh Shares
SBICAP Trustee Company Limited has released the encumbrance on 26,48,300 equity shares of Ginni Filaments Limited.
The released shares account for 3.09% of the company's total voting share capital. The transaction was executed on October 29, 2026.
SBICAP Trustee Company Limited was acting as a Security Trustee in relation to the encumbered shares held on behalf of lenders or debenture holders.
The disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Ginni Filaments Revised Encumbered Shareholding
Before the transaction, SBICAP Trustee Company Limited had 1,04,08,300 equity shares under encumbrance, representing 12.15% of Ginni Filaments' total voting share capital.
Following the release of 26,48,300 shares, the encumbered shareholding declined to 77,60,000 equity shares, representing 9.06% of the company's total voting share capital.
The transaction resulted in a reduction of 3.09 percentage points in the disclosed encumbered shareholding.
Ginni Filaments Transaction Highlights
- Company: Ginni Filaments Limited
- Entity involved: SBICAP Trustee Company Limited
- Entity classification: Security Trustee
- Transaction type: Release of encumbrance (pledge release)
- Shares released: 26,48,300 equity shares
- Percentage of shares released: 3.09%
- Pre-transaction encumbered holding: 1,04,08,300 shares (12.15%)
- Post-transaction encumbered holding: 77,60,000 shares (9.06%)
- Transaction date: October 29, 2026
- Promoter/promoter group association: No
- Regulatory disclosure: Regulation 29(2) of SEBI SAST Regulations, 2011
- Additional disclosure: Form D under SEBI (Prohibition of Insider Trading) Regulations, 2015
What to Watch Next
- Investors may track subsequent disclosures from Ginni Filaments Limited for updates concerning changes in its shareholding and encumbrance position.
- Further regulatory filings may provide information about additional pledge releases or changes in shares held under encumbrance arrangements.
- Investors can also monitor stock exchange disclosures for updates concerning the company's shareholding structure and other regulatory developments.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
Natco Pharma Promoters and Promoter Group Acquire 22.11 Lakh Shares Through Rights Issue
Natco Pharma Limited’s promoters and promoter group entities have acquired 22,11,776 equity shares through the company’s Rights Issue. The shares were allotted on October 26, 2026, at Rs 750 per share, taking the total value of acquisition to about Rs. 165.88 crore. The company’s paid up equity share capital increased to 19,61,67,952 equity shares following the Rights Issue.
Jio Financial Services Allots 25 Crore Shares to Promoter Group Entities
Jio Financial Services Limited has allotted 25 crore equity shares to two promoter group entities following the conversion of preferential warrants. The allotment was made at Rs.316.50 per share, including a face value of Rs.10 and a premium of Rs.306.50 per share.
Sun Pharma Gets US FDA Approval for ILUMYA to Treat Psoriatic Arthritis
Sun Pharmaceutical Industries has received US FDA approval for ILUMYA (tildrakizumab-asmn) to treat adults with active psoriatic arthritis (PsA). The approval expands the drug's use beyond plaque psoriasis and gives the company access to another segment of the US immunology market.